| Characteristic |
Number of Patients (%) |
| Median age, years (range) |
56 (31-86) |
| Gender – male |
24 (53%) |
| Female |
21 (47%) |
| Histology – adenocarcinoma |
13 (29%) |
| poorly differentiated adenocarcinoma |
12 (27%) |
| poorly differentiated carcinoma |
15 (33%) |
| squamous carcinoma |
5 (11%) |
| Number of metastatic sites – 1 |
9 (20%) |
| 2 |
15 (33%) |
| >3 |
21 (47%) |
| Metastatic sites – liver |
27 (60%) |
| lung |
23 (51%) |
| lymph nodes |
23 (51%) |
| soft tissue |
8 (18%) |
| bone |
6 (13%) |
| peritoneum |
6 (13%) |
| pancreas |
4 (9%) |
| adrenal gland |
2 (4%) |
| kidney |
2 (4%) |
| mediastinum |
2 (4%) |
| pelvis |
2 (4%) |
| pleura |
2 (4%) |
| spleen |
2 (4%) |
| colon |
1 (2%) |
| ovary |
1 (2%) |
| pericardium |
1 (2%) |
| stomach |
1 (2%) |
| First-line therapy – taxane/platinum-based |
38 (84%) |
| gemcitabine/irinotecan |
7 (16%) |
| Response to first-line therapy – CR/PR |
9 (20%) |
| Stable |
18 (41%) |
| PD |
11 (24%) |
| Unevaluable |
6 (13%) |
| Unknown |
1 (2%) |
